Clinical Trial Update: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II single-arm pilot study of the Chk1/2 inhibitor LY2606368 in BRCA1/2 mutation-associated breast or ovarian cancer, triple negative breast cancer, high-g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• LY2606368 (prexasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Cancer, Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-09-10